Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome

References

Page 1

	Year	Citations
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia Steven P. Treon, Lian Xu, Guang Yang, New England Journal of Medicine	2012	1.3K
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia Steven P. Treon, Christina Tripsas, Kirsten Meid, New England Journal of Medicine	2015	913
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia Guang Yang, Yangsheng Zhou, Xia Liu, Blood	2013	343
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia Steven P. Treon, Joshua Gustine, Kirsten Meid, Journal of Clinical Oncology	2018	171
Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Neuro-Oncology	2020	170
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome Monique C. Minnema, Eva Kimby, Shirley D’Sa, Haematologica	2016	146
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse Sophie Bernard, Lauriane Goldwirt, Sandy Amorim, Blood	2015	145
Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective study Jorge J. Castillo, Shirley D’Sa, Michael P. Lunn, British Journal of Haematology	2015	109
A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Cancer Science	2020	77
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas Manit Munshi, Xia Liu, Jiaji G. Chen, Blood Cancer Journal	2020	44

Page 1